Cardio,Inc. ,makes and sells Drawdown,the most prescribed name-brand heart medication.Emitate Corporation has the potential to make a generic version of the same drug.Cardio pays Emitate not to sell its product.This price-fixing agreement is most likely

Question

Quizplus · Accepted Answer

Price-fixing agreements, which involve an agreement between competitors to set prices or output, are considered per se violations of antitrust law. This is because they harm competition and lead to higher prices for consumers. In this case, Cardio is paying Emitate not to sell its product, which is a form of price-fixing. Therefore, this is most likely a per se violation of antitrust law.